Screening for Hepatitis B, C, and HIV among Drug Users

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to implement dedicated monthly screening days for viral hepatitis B, C, and HIV among drug users in non-conventional settings. Health professionals, including hepatologists and addiction specialists, will provide individualized care and management during these screening events. Patients will undergo various tests, including TRODs and FibroScan®, with results communicated confidentially. The study seeks to enhance access to screening and treatment for vulnerable populations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult 18 and over
* Patient frequenting an unconventional structure "outside the walls" or referred by a professional in the care sector
* Patient who agreed to participate to the research

Exclusion Criteria:

* Patient doesn't agree to participate to the research

Where it's running

• Chu Limoges
  Limoges, Haute Vienne, France Recruiting

Study contacts

• Principal investigator: Marilyne DEBETTE-GRATIEN, MD — Hôpital Dupuytren
• Study coordinator: Marilyne DEBETTE-GRATIEN, MD
• Email: MARILYNE.GRATIEN@chu-limoges.fr
• Phone: 33 5 55 05 87 26

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Glecaprevir/pibrentasvir started during pregnancy for women with hepatitis C, with or without HIV

  This trial will test whether taking glecaprevir/pibrentasvir during pregnancy is safe and how the drug is processed in pregnant women who have hepatitis C, including those who also have HIV, and will follow their infants for 10 weeks after birth.

  Recruiting at 8 sites Phase 1/2 National Institute of Allergy and Infectious Diseases (NIAID) · Los Angeles, California and 9 other locations · NCT07040319

• Evaluating hepatitis C treatment during pregnancy

  This study tests how well a new hepatitis C treatment works for pregnant adults with a history of drug use and looks at their experience during the treatment.

  Recruiting at 2 sites Washington University School of Medicine · St Louis, Missouri and 1 other locations · NCT06367465

• Decentralized treatment for hepatitis C in Brazil

  This study is testing a new way to treat hepatitis C in Brazil using a medication called Epclusa to see if it helps more people get the care they need compared to traditional methods.

  Recruiting at 2 sites Phase 4 Oswaldo Cruz Foundation · Rio de Janeiro, Rio de Janeiro and 1 other locations · NCT06306300

• Helping young people who inject drugs start treatment for Hepatitis C

  This study tests a new support program to help young adults who inject drugs start treatment for Hepatitis C and see if it works better than regular care.

  Recruiting University of California, San Francisco · San Francisco, California · NCT06179498

• Simplified hepatitis C testing with same-day treatment for people who inject drugs in Armenia, Georgia and Tanzania

  This project will test whether a simplified pathway that starts hepatitis C treatment the same day after a quick antibody test helps people who inject drugs in Armenia, Georgia, and Tanzania get treated and cured faster than the usual antibody-plus-RNA pathway.

  Recruiting Early Phase 1 Médecins du Monde · Yerevan · NCT06159504

• Understanding stress responses in individuals with alcohol use disorder

  This study looks at how people with alcohol use disorder react to stress and whether these reactions affect their cravings and drinking habits over time.

  Recruiting at 2 sites Central Institute of Mental Health, Mannheim · Mannheim, Baden-Wurttemberg and 1 other locations · NCT06105853

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.